
Sliding vaccine rates hang over vote on CDC director nominee as US measles cases hit dangerous milestone
There have been more measles cases in the US this year than any other since the disease was declared eliminated a quarter-century ago, according to CDC data, with at least 1,288 confirmed cases.
Just halfway through the year, the case tally has already surpassed the previous record from 2019, when there were a total of 1,274 cases. And it's well above the average of about 180 measles cases that have been reported each year since the disease was declared eliminated in the US in 2000.
CNN reported this new milestone on Saturday using data from the Johns Hopkins University Center for Outbreak Response Innovation, which updates its numbers more frequently than the CDC.
HHS has not responded to CNN's request for comment about the measles milestone.
Childhood vaccine coverage has been declining in the US, and the vast majority of measles cases this year – more than 90% – have been in people who were unvaccinated or whose vaccination status was unknown, according to the CDC.
When the measles case count reached its previous record in 2019 – during the first Trump administration – both the CDC director and the secretary of the US Department of Health and Human Services at the time released statements emphasizing the safety and effectiveness of the measles-mumps-rubella (MMR) vaccine and encouraging Americans to get vaccinated.
However, almost six months into Trump's second term, the CDC still does not have a director and HHS Secretary Robert F. Kennedy Jr. has a long and complicated history with measles vaccines.
Concerns about vaccine skepticism were front and center Wednesday as members of the Senate Health, Education, Labor and Pensions Committee voted to advance President Donald Trump's nominee to lead the CDC, Dr. Susan Monarez, for a vote by the full Senate.
Committee members voted 12-11 to move Monarez's nomination. All of the committee's Republicans backed the longtime immunologist and government scientist, who spoke in her confirmation hearing about restoring trust in the CDC and defended Kennedy's decision to replace the members of a federal panel of vaccine advisers.
The vote puts Monarez one step closer to taking the helm at the public health agency, and she will now progress to a full Senate vote.
HELP Chairman Sen. Bill Cassidy, a Louisiana Republican and a doctor, voted to advance Monarez's nomination but nodded to falling vaccine coverage and the ongoing measles outbreak.
'Dr. Monarez will work to modernize our data health systems, to improve public health coordination and response while protecting American sensitive health information,' Cassidy said. 'This is especially crucial as the nation combats reemerging public health threats like measles, which has taken three lives in the United States this year.'
He continued: 'One that's not included but is tragic: A Canadian woman who was pregnant got exposed to measles and lost her child. [The ongoing outbreak has] hospitalized many more due to misinformation regarding the measles vaccine.'
Cassidy publicly pressed Kennedy last month to delay a meeting of the health agency's new vaccine advisers — several of whom have expressed skepticism and safety concerns about long-approved immunizations — amid concerns about their biases.
During Wednesday's meeting, Sen. Patty Murray, a Washington Democrat, called on the committee to hold a hearing about the ongoing measles outbreak and Kennedy's shakeup of vaccine oversight.
'I am concerned because this committee, it feels like, has all but abandoned its serious oversight of this crisis,' she said. 'We haven't had a hearing on the record-breaking number of measles outbreaks or a hearing on how the CDC vaccine panel is now stacked with people who are actually not vetted, and all the previous board members, every single one of them, was removed with no credible explanation.'
There needs to be congressional oversight of these actions, Murray said after casting a vote against Monarez.
'I really do hope that Dr. Monarez will defy my expectations. I hope she will stand up for science and put public health first. But again, I hope I have hoped that for others, and here we are today,' she said.
Some health experts have emphasized the importance of vaccination rates and their trepidation about precedents being set under Kennedy's leadership of HHS.
'It is no surprise that the most widespread measles outbreak affecting the United States in a generation has occurred under Secretary Kennedy's watch,' Dr. Richard Besser, president and CEO of the Robert Wood Johnson Foundation and former acting director of the CDC, said in a statement Wednesday.
'His decades-long campaign to discredit vaccines at every turn, which has continued unabated during his time as health secretary, directly contributes to the alarming decline in routine childhood vaccination rates in our country that is resulting in more frequent outbreaks of vaccine-preventable diseases,' he said. 'In addition, the dramatic funding cuts to public health will mean that small outbreaks will grow and spread.'
Three people have died of measles in the US this year – two children in Texas and one adult in New Mexico, all of whom were unvaccinated – matching the total number of US measles deaths from the previous two and a half decades.
'I worry that even more children will be forced to pay with their lives or health because of Secretary Kennedy's malfeasance,' Besser said. 'As a pediatrician, I strongly encourage all parents to talk to their healthcare providers, listen to their local public health officials, and learn the facts about measles vaccines, which are incredibly effective and safe.'
The MMR vaccine is highly effective. One dose offers 93% protection against measles, and two doses are 97% effective, according to the CDC.
'Vaccines work—full stop. They are one of the most powerful tools we have to protect patients, families and entire communities. We can prevent diseases through vaccines, but too many diseases that we once had under control are starting to reappear because people are choosing to delay or skip immunization,' Dr. Jennifer Brull, president of the American Academy of Family Physicians, said in a statement.
'There's a lot of confusion around vaccinations, but patients don't have to navigate this alone. Family physicians, pediatricians, pharmacists and other public health workers can help patients wade through all the information and cut through the noise,' she said. 'The bottom line is vaccines are safe, effective and save lives. It's critical that we continue to protect not just individual families, but the health of our entire nation.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Molina Healthcare (MOH) Announces Preliminary Results For Q2 2025
Molina Healthcare, Inc. (NYSE:MOH) is one of the On July 7, Molina Healthcare, Inc. (NYSE:MOH) announced its preliminary financial results for the fiscal second quarter of 2025 along with an update to its full-year EPS guidance. As per the latest update, Molina Healthcare, Inc. (NYSE:MOH) expects second quarter earnings around $5.50 per share, reflecting a modest decline from the previous expectation. The decline is due to the medical cost pressure across all three lines of business. Management noted that this pressure is expected to stay for the rest of the year. A doctor in scrubs shaking hands with a patient, representing the healthcare services provided to individuals and families. As a result, the company also adjusted its full-year 2025 earnings outlook. Molina Healthcare, Inc. (NYSE:MOH) now expects to earn between $21.50 and $22.50 per share for the year. This range is at the low end of its long-term targets. The company's CEO, Joseph Zubretsky, explained the situation, noting the short-term drop in earnings was due to a gap between how fast medical costs are rising and how quickly premium rates are adjusted. He called this a temporary issue and noted that the company's long-term outlook is unchanged, even with possible effects from new budget laws. Molina Healthcare, Inc. (NYSE:MOH) is a managed care company that provides health insurance and healthcare services mainly through government programs like Medicaid and Medicare. While we acknowledge the potential of MOH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Rhythm's stock climbs on encouraging Phase II obesity drug data
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses. The Phase II study (NCT06046443) was investigating the therapy in patients with acquired hypothalamic obesity. Patients can also remain on the open-label extension of the study for 52 weeks. Topline data from the study has shown a 9.3% reduction in BMI in the high dose cohort (600mg), a 7.7% reduction in the medium dose cohort (400mg) and a 2.7% reduction in the low dose cohort (200mg) after 14 weeks. The placebo group saw a 2.2% increase in BMI. The BMI reduction achieved by bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, was consistent with BMI reductions achieved with Rhythm's Imcivree (setmelanotide) therapy in similar patient populations in past trials. Patients in the high and medium dose cohorts achieved a mean reduction greater than 2.8 points in their 'most' hunger scores measured on a TEN-point scale. Patients in the low-dose arm achieved a mean reduction of 2.1 points, while patients on placebo therapy reported a mean increase of 0.8 points. The therapy also remained safe and tolerable in the study, consistent with other therapies in the MC4R agonism. On 9 July, Rhythm's stock, listed on the Nasdaq exchange, closed 36.63% higher at $89.00 compared to an 8 July close of $65.14. Rhythm Pharmaceuticals has a market cap of £5.66bn. Rhythm Pharmaceuticals' CEO Dr David Meeker said: 'We are excited by these results, which suggest bivamelagon has the potential to treat patients with acquired hypothalamic obesity, and has established an appropriate dose range for future clinical evaluation. Unlike in studies evaluating general obesity, once again we observed no placebo effect in this study.' Meeker said that Rhythm will be speaking with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the Phase III trial design of bivamelagon. Rhythm in-licensed bivamelagon from LG Chem in January 2024, with a $40m upfront payment and $20m in equity. Rhythm will also provide LG Chem with an additional $205m upon reaching certain regulatory and sales milestones. This is yet another positive readout for an oral obesity medicine. Last month, Novo Nordisk's amycretin, which is available in both subcutaneous and oral dosing, showed weight loss of up to 22% after 36 weeks, with the drug set to advance to Phase III. Furthest ahead in the game is Eli Lilly, with its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) orforglipron having shown benefit in a Phase III trial. Lilly plans to submit the therapy for approval by the end of 2025, with a type 2 diabetes application to follow in 2026. GlobalData predicts the obesity market will continue to grow as new products are released, reaching $206.5bn in 2031. GlobalData is the parent company of Clinical Trials Arena. "Rhythm's stock climbs on encouraging Phase II obesity drug data" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Editorial: Golden age for disease: RFK presides over rampant measles
Proving once again that anti-vax quack Health and Human Services Secretary Robert F. Kennedy Jr. is a threat to public health, confirmed measles cases in the United States have hit a 33-year high. It's even worse since it's been a quarter century since the deadly disease was declared completely eradicated in the country. But no more. The nearly 1,300 confirmed cases across 38 states and D.C. are likely only a fraction of total numbers, given just how infectious the virus is. Meanwhile, RFK Jr., tasked with safeguarding the health of people around the country, has done practically as much or more than anyone else to bring measles back, both in his long career as a prominent anti-vaxxer peddling falsehoods for profit through his ill-fated current position atop the nation's health infrastructure. There's a tendency among Kennedy and the Make America Healthy Again folks to paint the spread of these infectious diseases as simply something that happens naturally, and which we should therefore just let play out. Pathogens certainly did emerge from nature and have long been part of our environment, but that doesn't make them something inherent to our lives in the same way that we wouldn't any longer consider it a fact of life for people to be eaten by animals or starving from crop failures, as our pre-scientific ancestors did. In fact, these disease-ridden forebears would be floored that people in our society, and especially those in charge, would actually choose to re-introduce what they considered horrible problems since solved. How short are the memories that vaccine hesitancy and a repudiation of medical science are gaining steam. In the days before vaccines, smallpox and polio and measles killed. For years, American parents have been spared having to watch their kids die of the measles; in fact, up until this year, none had so in this country for a decade. But, unfortunately, there will be more as the extraordinarily virulent pathogen continues to tear around the country. It's sad to think that we are doomed to relearn lessons forgotten, but we are at a crucial point now where it's possible to avoid this fate. The spread of measles is still controllable with close coordination and aggressive intervention by a federal government that understands the stakes and the level of risk. Tragically, it doesn't seem like we are going to have one anytime soon, so the next best thing will have to be to force federal authorities to act. This week, a group of major medical organizations, including the American Academy of Pediatrics and the American College of Physicians filed a lawsuit in Boston Federal Court, making the case that recommendations issued by RFK's handpicked new vaccine advisory panel — which replaced an existing panel of experts all fired by the professional anti-vaccine agitator— were void and his actions unlawful. Their arguments centered on new recommendations around upcoming COVID boosters, but their efforts could just as well extend to other vaccines and therapeutics, given that Bobby Kennedy seems perfectly willing and able to target them all. This is not a game; until the kooks and zealots rampaging over the public health infrastructure are constrained, many people could die. ___